Company news
Nutriband Inc. (NASDAQ:NTRB) news
Nutriband Inc. news releases on 6ix. Latest, Oct 1, 2026: Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Press releases & updates
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
October 1, 2026
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
September 28, 2026
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
September 25, 2026
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
September 22, 2026
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
September 9, 2026
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
September 8, 2026
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
August 13, 2026
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
May 15, 2026
Nutriband : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)
April 29, 2026
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
April 22, 2026
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
March 29, 2026
Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
March 17, 2026
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
February 17, 2026
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
January 30, 2026
Nutriband CEO Publishes Letter to Shareholders
December 31, 2025
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
December 29, 2025
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
December 18, 2025
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
December 18, 2025
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
November 24, 2025
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
October 28, 2025
Nutriband Co-Founder Gareth Sheridan Returns as CEO
October 27, 2025
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
October 10, 2025
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
October 8, 2025
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
October 8, 2025
Nutriband Inc. to Present at the MicroCap Rodeo Conference
September 24, 2025
Nutriband : Publishes Q2 Report and Announces Key FDA Meeting for AVERSA™ Fentanyl
September 12, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
September 10, 2025
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
September 3, 2025
Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025
August 18, 2025
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
August 11, 2025
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
August 8, 2025
Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
July 18, 2025
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
July 2, 2025
Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
July 1, 2025
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
June 18, 2025
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
June 9, 2025
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
June 3, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
June 2, 2025
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
April 11, 2025
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
April 4, 2025
Nutriband Signs Partnership Agreement with Charlotte FC
April 4, 2025
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
February 21, 2025
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
February 12, 2025
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
February 10, 2025
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
February 6, 2025
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
December 26, 2024
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
December 3, 2024
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
November 26, 2024
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
October 16, 2024
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
September 23, 2024